Biopharma News : Biopharma and Pharma news from all around the world :
- Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress
- Organigram Global Expands FAST™ Innovation Platform with SHRED Shotz, Leveraging SHRED Brand Equity
- Intelligent Manufacturing in China Sets a New Benchmark for Design: GUTX Probiotic Dual-Compartment Fresh Probiotics Wins the 2025 French Design Awards
- GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.
- Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency
- Allosteric Bioscience, Inc. Targets Optimizing Aging and Longevity: Quantum Computing, Advanced AI, Genomics
- Allosteric Bioscience, Inc. Targets Extending Longevity
- Vasomune Therapeutics, Inc., and AnGes, Inc., Announce US FDA Clearance of Investigational New Drug (IND) Application For Pegevongitide (AV-001) Treatment in Resuscitation of Severely Burned Patients
- Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM)
- Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America
- Poplar Therapeutics Closes $45 million Series A Extension to Advance Development of Lead Program, PHB-050, A New Class of Anti-IgE Therapy for Multiple Atopic Conditions
- Sanaregen™ Vision Therapeutics Receives FDA Clearance for Clinical Trial to Treat Retinal Degeneration
- BioTalent Canada Breaks Barriers in Opening Applications for 2026 I.D.E.A.L. Scholarship™
- Lucidis® Sets High Standards in Premium Cataract Surgery with Full-Range Vision Performance
- Dxcover Secures CE-IVDR Certification
- Linnea Achieves CEP Certification for Cannabidiol Isolate
- Zura Bio to Participate in Upcoming Investor Conferences
- Wisdom Bioscience Establishes Scientific Advisory Board to Advance Oral Cancer Diagnostics and Screening
- Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
- Genentech’s Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)
- PHCbi Launches LiCellGrow™ Cell Expansion System to Support High-Quality and Efficient Production of Cell and Gene Therapies
- Otsuka Medical Devices/Otsuka Pharmaceutical: Paradise Ultrasound Renal Denervation System for the Treatment of Resistant Hypertension, Now Covered by Insurance and Commercially Available in Japan
- KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)
- WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
- Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
- Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
- National Condom Month: Why Today’s Protection Is About Pleasure, Confidence and Connection, According to Sex & Relationship Expert, Dr. Deb Laino
- Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025
- Prothena Announces up to $100 Million Share Repurchase Plan
- AOP Health on Rare Diseases: Information. Collaboration. Innovation.
News about Biotech, Pharma, Biopharma, Medical Devices, Diagnostics, Digital Health
- Cellbox Solutions closes first tranche of Series A financing and appoints new CBO/CFO to accelerate international growth
- BioVersys to Report its Full Year 2025 Financial Results, Provide a Business Update and Host a Conference Call
- Formycon AG publishes preliminary figures for the 2025 fiscal year
- BioVersys Announces Publication of BV100 Phase 1 Clinical Data in Journal of Antimicrobial Agents and Chemotherapy
- Viromed Medical AG signs letter of intent to acquire relyon plasma GmbH – Strategic step toward integrated platform for cold plasma technology
- Viromed Medical AG signs letter of intent to acquire relyon plasma GmbH
- Immunic to Participate in Investor Conferences in March
- Secarna Pharmaceuticals and Curie.Bio Expand Existing Partnership
- NVision Establishes First Strategic European Hub at University of Cambridge to Advance Clinical Translation of Quantum-Enhanced Metabolic MRI
- VERAXA Biotech Receives 99.57% Approval for Merger – Path to NASDAQ Listing Under «VRXA» Cleared
- MindMaze Therapeutics Provides Corporate Update and Publishes March 2026 Investor Presentation
- DocMorris AG announces changes to its Board of Directors
- Beiersdorf Aktiengesellschaft: Guidance 2026 –– New Share Buyback Program
- O3 Holding GmbH: O3 Holding GmbH – Publication Q4 2025 Interim Report
- Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
- Eckert & Ziegler Enters Partnership with Molecular Partners to Support Development of Radio-DARPin Therapeutics
- Gerresheimer AG: BaFin announces expansion of audit of 2024 consolidated financial statements and initiation of audit of 2025 Half-Year Financial Report
- BIO-Europe Spring® 2026 Charts the Future of Life Sciences from Lisbon’s Shores
- Darwin AG Announces Preliminary Group Revenue for 2025 and Confirms Strategic Growth Trajectory
- BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds
- Pentixapharm Receives FDA “Study May Proceed” Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program
- #FutureFresenius: REJUVENATE in action – Delivering accelerated performance for long-term value creation; 2025 yet another year of strong delivery
- Sandoz delivers strong full-year results; guidance for 2026 reflects an expected acceleration in growth
- Formycon announces positive clinical data for Keytruda® biosimilar candidate FYB206 (pembrolizumab)
- Fresenius Supervisory Board extends ahead of schedule CEO Michael Sen’s contract by five years — Christian Pawlu to join Management Board for Fresenius Helios effective July 1, 2026
- CF PharmTech (HKEX: 2652.HK) Announces NMPA Acceptance of IND Application for ICF004, a Potential First-in-Class Inhaled Dry Powder Candidate Targeting Unmet Needs in PF-ILD
- Promatix Biosciences Presents Positive Preclinical Data with First-in-Class PBS293 EGFR×EphA2 Cis-Bispecific ADC Demonstrating Enhanced Tumour Selectivity
- Galenica focuses Bichsel’s business on home care services
- Sandoz confirms European Commission approval for Ranluspec® (ranibizumab), further strengthening overall biosimilars leadership and position in ophthalmology
- DocMorris receives TÜV certification for temperature-controlled delivery of pharmaceuticals
- Hopewell Therapeutics Announces Sublicense of Proprietary Lipid Nanoparticles for Novel Cancer Vaccine to Foxcroft Therapeutics
- Evaxion announces business update and full year 2025 financial results
- Vera Therapeutics Appoints Christopher Hite to Board of Directors
- NTG Nordic Transport Group A/S – Notice to convene the Annual General Meeting 2026
- Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
- Evaxion plans to file 2025 annual report later today
- Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
- Collegium to Present New Real-World Data at PainConnect 2026
- BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026
- Galimedix Therapeutics to present promising pre-clinical data with next generation oral amyloid beta aggregation modulator at AD/PD™ 2026 Conference
- Oculis to Participate in Upcoming Investor Conferences
- Oculis Publishes 2025 Consolidated Financial Statements
- Oculis to Participate in Upcoming Investor Conferences
- Press Release: Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director
- Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals
- SugarHarmony Consumer Concerns Under Investigation: Critiquing The Sugar Harmony Claims
- Purisaki Berberine Patches Claims Evaluated: 2026 Consumer Report on Transdermal Berberine Delivery, Patch Absorption Science, and What Buyers Should Verify
- Medline Inc. announces pricing of secondary offering of class A common stock
- HealthRecon Connect Achieves HITRUST r2 Certification Demonstrating the Highest Level of Information Protection Assurance
- Medline Inc. announces pricing of secondary offering of class A common stock
- HealthRecon Connect Achieves HITRUST r2 Certification Demonstrating the Highest Level of Information Protection Assurance
- The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
- AURORA SPINE CORPORATION ANNOUNCES AMENDMENT TO LOAN FROM INSIDER
- Actuate Therapeutics to Present at The Citizens Life Sciences Conference
- Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08
- Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment
- FemPulse Pivotal Study Selected For Presentation at the American Urological Association Annual Conference
- Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
- Baylor Genetics to Highlight New Data and Product Innovations at 2026 ACMG Annual Clinical Genetics Meeting
- Standard Process® Launches Canine Cognition Support to Help Aging Dogs Maintain Brain Health
Sources for this page of Biopharma News : biopharma-reporter.com and worldpharmanews and pharmatimes.com and drugs.com and fiercepharma.com and scripintelligence.com and PR Newswire and Business Wire. Please visit all this very interesting websites for more info.
Biopharma News – Pharma News